












# MASTER TRIAL LIST

JUNE 2023

 New or ReOpened Trials  
 No Trials Currently Available

## JUST IN TIME TRIALS (JIT)

 AML	 ANAL	 ALL
 APL	 BILIARY	 BLADDER-UROTHELIAL
 BRAIN	 BREAST/ GYN	 CANCER CONTROL
 CLL	 CML	 COLON-RECTAL
 ESOPHAGEAL - GASTRIC	 HEAD & NECK	 LYMPHOMA
 MDS/MPN	 MELANOMA	 MERKEL
 MOLECULAR STUDIES	 MULTIPLE MYELOMA	 NEUROENDOCRINE
 NSCLC	 PANCREATIC	 PROSTATE
 RADIATION TRIALS	 RENAL CELL	 SMALL CELL LUNG CANCER

Updated 6.6.23

### RADIATION LOCATIONS:

OSF Glen Oak - OSF main hospital  
OSF Route 91 (attached to Illinois CancerCare)  
Carle Health Greater Peoria  
Galesburg - Western Illinois Cancer Treatment Center  
SJMC - St Joseph Medical Center



**JUST IN TIME (JIT) TRIALS**

\*Contact Disease Specific Navigator

**Multi-Disease Site: Advanced/Metastatic Solid Tumors**

**EAY191**  
**(Combomatch) - S3**

*Molecular Analysis for combination Therapy Choice* **(SUBSTUDY- S3: A Phase II Study of Paclitaxel + Ipatasertib In Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors)**

**RAIN-3202**

A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors

**ALL**

**EA9213**

A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL)

**Breast**

**EAY191**  
**(Combomatch) - N2**

*Molecular Analysis for combination Therapy Choice* **(SUBSTUDY- N2: Phase II Trial of Fulvestrant and Binimetinib in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With A Frameshift or Nonsense Mutation or Genomic Deletion in NF1)**

**Gynecological**

**EAY191**  
**(Combomatch) - N4**

*Molecular Analysis for combination Therapy Choice* **(SUBSTUDY- N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers)**

**GY026**

A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma

**Genitourinary - Rare**

**A031702**

Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors *(temp closed cohorts - small cell carcinoma/neuroendocrine & adenocarcinoma of bladder, penile, and misc GU tract variants, renal medullary carcinoma, and rare GU)*

**Head & Neck**

<a href="#"><u>EA3191</u></a>	A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
<a href="#"><u>HN010</u></a>	A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naive, Unresectable HER2-Positive Salivary Gland Cancer
<b>Liposarcoma</b>	
<a href="#"><u>A092107</u></a>	A Randomized Phase 2 Trial With a Safety Lead-In to Evaluate Palbociclib Versus Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated Liposarcoma
<b>Neuroendocrine</b>	
<a href="#"><u>S2104</u></a>	Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
<b>Pancreas</b>	
<a href="#"><u>S2104</u></a>	Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
<b>Rectal</b>	
<a href="#"><u>EA2201</u></a>	<b>Temporarily Closed (RT at Glen Oak, UPHM, Galesburg)</b> A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma
<b>Skin</b>	
<a href="#"><u>A091802</u></a>	Phase II randomized Trial of Avelumab plus cetuximab versus avelumab alone in advanced cutaneous Squamous cell carcinoma of skin



ILLINOIS  
CANCERCARE, P.C.

*Specializing in Cancer and Blood Disorders*

# MASTER TRIAL LIST

JUNE 2023

[MENU](#)

*AML*

Navigator - Heather x3661



# MASTER TRIAL LIST

JUNE 2023



## ANAL

Navigator - Carrie x3621

<a href="#"><u>EA2176</u></a>	A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients
<a href="#"><u>EA2182</u></a>	<b>(RT at Carle and Glen Oak)</b> A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)



ILLINOIS  
CANCERCARE, P.C.

*Specializing in Cancer and Blood Disorders*

# MASTER TRIAL LIST

JUNE 2023

[MENU](#)

*APL*

Navigator - Heather x3661

*There are no trials available at this time*



# MASTER TRIAL LIST

JUNE 2023



## ACUTE LYMPHOBLASTIC LEUKEMIA

Navigator - Heather x3661

[EA9213 - JIT Trial](#)

A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL)



ILLINOIS  
CANCERCARE, P.C.

*Specializing in Cancer and Blood Disorders*

# MASTER TRIAL LIST

JUNE 2023

[MENU](#)

***BILIARY***

Navigator - Carrie x3621

No trials available at this time





# MASTER TRIAL LIST

JUNE 2023



## BLADDER / UROTHELIAL

Navigator - Carrie x3621

### ADJUVANT / NEOADJUVANT

<a href="#"><u>EA8185</u></a>	<b>(RT pending at Glen Oak &amp; Rt-91)</b> Phase 2 Study of Bladder-Sparing Chemoradiation With MEDI4736 (Durvalumab) in Clinical Stage 3, Node Positive Bladder Cancer (INSPIRE)
<a href="#"><u>S1806</u></a>	<b>(RT at Glen Oak, SJMC, Carle and Galesburg)</b> Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer
<a href="#"><u>S2011</u></a>	Randomized Phase II Trial of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma: SWOG GAP TRIAL
<b>METASTATIC</b>	
<a href="#"><u>A032001</u></a>	Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients With Metastatic Urothelial Cancer
<a href="#"><u>A032002</u></a>	<b>Temporarily Closed (RT at Glen Oak)</b> Phase II Randomized Trial of Atezolizumab Versus Atezolizumab and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (ART)



# MASTER TRIAL LIST

JUNE 2023



## BRAIN

Navigator - Carrie x3621

<a href="#"><u>A071702</u></a>	A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
<a href="#"><u>BN011</u></a>	<b>(RT credentialing pending)</b> A Phase III Trial of Gleostine® (Lomustine)-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients With Methylated MGMT Promoter Glioblastoma
<a href="#"><u>N0577</u></a>	<b>(RT at Glen Oak, RT 91, and Carle)</b> Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma



**BREAST**

Navigator - Angie x3613

**DCIS**

No trials at this time

**NEO/ADJUVANT TREATMENT**

S1706\*

**Not Actively Screening - Contact Navigator** - A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer (**All biomarker subgroups eligible**) | \*JIT TRIAL - expect 1 week delay to consent pt

**Neo/Adjuvant - HER2 Positive**

A011801

The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib

EA1181

Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response (CompassHER2-pCR) (*Closed to Her2+/ER+ w/ tumor 2.1-3cm and node negative; ER negative cohort closed*)

**Neo/Adjuvant - Hormone Receptor Positive / HER2 Negative**

BR007

(RT at Galesburg, Glen Oak, Rt 91, Carle, SJMC) Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer

JSJ-MC-JZLH / EMBER-4

(Peoria, Bloomington, Galesburg, Pekin, Washington, Ottawa, Peru) A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestran vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence

**Neo/Adjuvant - Triple Negative**

A012103

**NEW!** OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy

**METASTATIC TREATMENT**

**Metastatic - HER2 Positive** (no trials at this time)

**Metastatic - Hormone Receptor Positive / HER2 Negative**

<u><a href="#">EAY191</a></u> <b>(Combomatch) - N2</b> <u><a href="#">(JIT)</a></u>	<i>Molecular Analysis for combination Therapy Choice</i> ( <b>SUBSTUDY- N2</b> : Phase II Trial of Fulvestrant and Binimetinib in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With A Frameshift or Nonsense Mutation or Genomic Deletion in NF1)
<u><a href="#">S1703</a></u>	Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer
<u><a href="#">S2007</a></u>	<b>Not Actively Screening - contact Navigator</b> - A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases
<b>Metastatic - Triple Negative</b> <i>(no trials at this time)</i>	
<b>SURGERY / RADIATION ONLY</b>	
<u><a href="#">MA.39</a></u>	Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer ( <i>RT: Glen Oak and Carle</i> )
<b>CANCER CONTROL (Breast only)</b>	
<u><a href="#">A211901</a></u>	<b>Not Actively Screening - Contact Navigator</b>   Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
<u><a href="#">A212102</a></u>	<b>(Peoria, BLM, Canton, Gburg, Pekin, Peru, Ottawa, Wash)</b> Blinded Reference Set for Multicancer Early Detection Blood Tests <i>(healthy cohort closed)</i>
<u><a href="#">A222004</a></u>	<b>Not Actively Screening - Contact Navigator</b>   A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
<u><a href="#">EAQ202</a></u>	Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials <i>(breast, leukemia, lymphoma, and white non-hispanic cohorts closed to accrual)</i>
<u><a href="#">S2010</a></u>	A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence With Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN)
<u><a href="#">S2108CD</a></u>	<b>(Peoria, Bloomington, Galesburg, Canton, Ottawa, Pekin)</b> A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
<u><a href="#">S1912CD</a></u>	<b>Not Actively Screening - Contact Navigator</b>   A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
<u><a href="#">S2013</a></u>	<b>(Peoria, Bloomington, Galesburg, Pekin, Washington)</b> Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study ( <b>I-CHECKIT</b> )

<a href="#"><u>URCC 16070</u></a>	Treatment of Refractory Nausea- for breast cancer patients.
<a href="#"><u>URCC-18007</u></a>	Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue- <i>at least 2 months out from surgery/tx/radiation</i>
<a href="#"><u>URCC 19185</u></a>	<b>(Peoria only)</b> Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia <b>(BBT-CI)</b> and Healthy Eating Education Learning <b>(HEAL)</b>
<a href="#"><u>URCC 21038</u></a>	<b>(Peoria, Bloomington, Galesburg, Pekin, Washington)</b> Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
<a href="#"><u>WF-1901</u></a>	Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)

### **GYNECOLOGICAL**

**Navigator - Angie x3613**

<a href="#"><u>NRG - GY023</u></a>	<b>Temporarily Closed</b> A Randomized Phase II Trial of Triplet Therapy (a PD-L1 Inhibitor (Durvalumab) MEDI4736 in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or (Durvalumab) MEDI4736 and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
<a href="#"><u>EAY191 (Combomatch) - N4</u></a>	<i>Molecular Analysis for combination Therapy Choice</i> <b>(SUBSTUDY- N4):</b> A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers)

## CANCER CONTROL

### MULTI-DISEASE SITES

<a href="#">A211901</a>	<b>Not Actively Screening - Contact Navigator</b>   Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
<a href="#">A212102</a>	<b>(Peoria, BLM, Canton, Gburg, Pekin, Peru, Ottawa, Wash)</b> Blinded Reference Set for Multicancer Early Detection Blood Tests <i>(healthy cohort closed)</i>
<a href="#">A222004</a>	<b>Not Actively Screening - Contact Navigator</b>   A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
<a href="#">EAQ202</a>	Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials <i>(breast, leukemia, lymphoma, and white non-hispanic cohorts closed to accrual)</i>
<a href="#">S1912CD</a>	<b>Not Actively Screening - Contact Navigator</b>   A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
<a href="#">S2013</a>	<b>(Peoria, Bloomington, Galesburg, Pekin, Washington)</b> Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study (I-CHECKIT)
<a href="#">S2108CD</a>	<b>(Peoria, Bloomington, Galesburg, Canton, Ottawa, Pekin)</b> A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
<a href="#">URCC-18007</a>	Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue - <i>at least 2 months out from surgery/tx/radiation</i>
<a href="#">URCC 19185</a>	<b>(Peoria only)</b> Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)
<a href="#">URCC 21038</a>	<b>(Peoria, Bloomington, Galesburg, Pekin, Washington)</b> Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
<a href="#">WF-1901</a>	Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)
<b>BREAST</b>	
<a href="#">S2010</a>	A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence With Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN)
<a href="#">URCC 16070</a>	Treatment of Refractory Nausea- for breast cancer patients.
<b>LUNG</b>	
JOVIALITY 23289	<b>(Peoria only) Safety and Acceptability: Virtual Reality for Psychotherapy Delivery in Lung Cancer Patients of Illinois CancerCare</b>

**COLORECTAL**

**WF-1806**

(M&M Study) Myopenia and Mechanisms of Chemotherapy Toxicity in older Adults with Colorectal Cancer

**BRAIN**

**WF-1801**

A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy

**REGISTRY**

**Navigator - Heather 243-3661**

**Connect Myeloid**

The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. (*enrolling cohorts: low risk MDS, Treated MF, Treated MF cytopenias - includes CMML, aCML, MDS/MPN-RS-T, MDS/MPN unclassifiable*)

**NHLBI-MDS**

**(Peoria, Bloomington and Galesburg only)** -The National Myelodysplastic Syndromes (MDS) Study



ILLINOIS  
CANCERCARE, P.C.C.C.

*Specializing in Cancer and Blood Disorders*

# MASTER TRIAL LIST

JUNE 2023

[MENU](#)

## CARCINOID

Navigator - Ashton x3611  
Carrie x3621

[A021602](#)

Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo In Patients With Advanced Neuroendocrine Tumors After progression on Prior Therapy (CABINET)





# MASTER TRIAL LIST

JUNE 2023



**CLL**

Navigator - Heather x3661

*no trials at this time*

**1st Line**

**2nd Line, 3rd Line, etc.**

# MASTER TRIAL LIST

JUNE 2023



*CML*

Navigator - Heather x3661

No trials currently available

# MASTER TRIAL LIST

MENU

JUNE 2023

## COLON / RECTAL

Navigator - Carrie x3621

### Adjuvant

<a href="#">C-14</a>	<b>(Peoria, Bloomington, Galesburg, Ottawa, Pekin, Peru, Washington)</b> Second Colorectal Cancer Clinical Validation Study to Predict Recurrence Using A Circulating Tumor DNA Assay To Detect Minimal Residual Disease ( <b>CORRECT-MRD II</b> )
<a href="#">EA2201 - JIT</a>	<b>Temporarily Closing 5.9.23 (RT at Glen Oak, Carle, Galesburg)</b> A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma
<a href="#">GI005</a>	Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
<a href="#">GI008</a>	Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

### Metastatic

<a href="#">S2107</a>	Randomized Phase II Trial of Encorafenib and Cetuximab With or Without Nivolumab (NSC #748726) for Patients With Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
-----------------------	--

### CANCER CONTROL (Colorectal only)

<a href="#">A211901</a>	<b>Not Actively Screening - Contact Navigator</b>   Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
<a href="#">A212102</a>	Blinded Reference Set for Multicancer Early Detection Blood Tests ( <i>healthy cohort closed</i> )
<a href="#">A222004</a>	<b>Not Actively Screening - Contact Navigator</b>   A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
<a href="#">EAQ202</a>	Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials ( <i>breast, leukemia, lymphoma, and white non-hispanic cohorts closed to accrual</i> )
<a href="#">A212102</a>	<b>(Peoria, BLM, Canton, Gburg, Pekin, Peru, Ottawa, Wash)</b> Blinded Reference Set for Multicancer Early Detection Blood Tests
<a href="#">S1912CD</a>	<b>Not Actively Screening - Contact Navigator</b>   A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
<a href="#">S2013</a>	<b>(Peoria, Bloomington, Galesburg, Pekin, Washington)</b> Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study ( <b>I-CHECKIT</b> )

<a href="#"><u>S2108CD</u></a>	<b>(Peoria, Bloomington, Galesburg, Canton, Ottawa, Pekin)</b> A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
<a href="#"><u>URCC-18007</u></a>	Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue - <i>at least 2 months out from surgery/tx/radiation</i>
<a href="#"><u>URCC 19185</u></a>	<b>(Peoria Only)</b> Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)
<a href="#"><u>URCC 21038</u></a>	<b>(Peoria, Bloomington, Galesburg, Pekin, Washington)</b> Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
<a href="#"><u>WF-1901</u></a>	Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)
<a href="#"><u>WF-1806</u></a>	(M&M Study) Myopenia and Mechanisms of Chemotherapy Toxicity in older Adults with Colorectal Cancer



# MASTER TRIAL LIST

JUNE 2023



## ESOPHAGEAL- GASTRIC

Navigator - Carrie x3621

[A022102](#)

Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma

## HEAD & NECK

Navigator - Ashton x3611

<a href="#"><u>EA3161</u></a>	<b>(RT at Glen Oak, Carle, Galesburg)</b> A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
<a href="#"><u>EA3191 - JIT</u></a>	A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
<a href="#"><u>HN005</u></a>	<b>REOPENED!</b> <b>(RT at Galesburg, Glen Oak)</b> A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
<a href="#"><u>HN009</u></a>	<b>(RT at Carle)</b> Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100 mg/m <sup>2</sup> ) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (40 mg/m <sup>2</sup> ) for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
<a href="#"><u>HN010 - JIT Trial</u></a>	A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naive, Unresectable HER2-Positive Salivary Gland Cancer
<a href="#"><u>S2101</u></a>	<b>Temporarily Closing 6.7.23</b>   Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Patients With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study



# MASTER TRIAL LIST

JUNE 2023

MENU

Navigator - Heather x3661

## LYMPHOMA

### HL

*No HL trials at this time*

### NHL



# MASTER TRIAL LIST

JUNE 2023



## MDS/MPN

Navigator - Heather x3661

<a href="#"><u>Connect Myeloid</u></a>	The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. ( <i>enrolling cohorts</i> : newly diagnosed low risk MDS, Treated low risk-MDS, Treated MF, Treated MF cytopenias - includes CMML, aCML, MDS/MPN-RS-T, MDS/MPN unclassifiable)
<a href="#"><u>NHLBI-MDS</u></a>	<b>(Peoria, Bloomington and Galesburg only)</b> -The National Myelodysplastic Syndromes (MDS) Study





# MASTER TRIAL LIST

JUNE 2023



## MELANOMA

Navigator - Carrie x3621

S2101

**Temporarily Closing 6.7.23** | Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Patients With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study



# MASTER TRIAL LIST

JUNE 2023



MENU

## MERKEL

Navigator - Carrie x3621

<p><a href="#"><u>EA6174</u></a></p>	<p><b>Temporarily Closed (RT at Glen Oak, Carle, Galesburg)</b> A Phase III Randomized Trial Comparing Adjuvant MK3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma</p>
--------------------------------------	---



# MASTER TRIAL LIST

JUNE 2023

MENU

## MOLECULAR STUDIES

\*Contact Disease Specific Navigator

<a href="#"><u>A151804</u></a>	Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
<a href="#"><u>S1823</u></a>	A Study of miRNA 371 in Patients With Germ Cell Tumor <i>(closed to high risk pts or pts on chemo for testicular cancer)</i>
<a href="#"><u>TP-CA-003 (Sculptor)</u></a>	<b>(Peoria, Blm, Canton, Gburg, Ottawa, Pekin, Peru, Washington)</b> A Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients with Small Cell Lung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays (TEMPUS)
<a href="#"><u>TPX-0005-01 (TRIDENT-1)</u></a>	A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with <b>Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements</b> (TRIDENT-1)

# MASTER TRIAL LIST

JUNE 2023



## MULTIPLE MYELOMA

Navigator - Heather x3661

<b>EAA173</b>	Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
<b><u>S1803</u></b>	<b>Temporarily Closed</b>   Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)

# MASTER TRIAL LIST

JUNE 2023

MENU

## NEUROENDOCRINE

Navigator - Carrie x3621

<a href="#"><u>A021602</u></a>	Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo In Patients With Advanced Neuroendocrine Tumors After progression on Prior Therapy (CABINET)
<a href="#"><u>A021804</u></a>	A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma
<a href="#"><u>S2104 - JIT Trial</u></a>	Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors



**NSCLC**

Navigator - Ashton x3611

**ADJUVANT / NEOADJUVANT**

<a href="#"><u>A081801</u></a>	Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ALCHEMIST substudy- <i>Must be enrolled on ALCHEMIST and this substudy prior to start of tx.</i> )
<a href="#"><u>A151216</u></a>	Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial ( <b>ALCHEMIST</b> ).
<a href="#"><u>EA5181</u></a>	<b>(RT at Glen Oak, Rt-91, Carle and Galesburg)</b> Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
<a href="#"><u>LU008</u></a>	<b>NEW! (RT credentialing pending)</b> Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer
<a href="#"><u>S1914</u></a>	<b>(RT at Glen Oak, Carle, Galesburg, SJMC)</b> Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

**METASTATIC - 1st Line**

<a href="#"><u>EA5163</u></a>	<b>REOPENED!</b> A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
<a href="#"><u>EA5182</u></a>	Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
<a href="#"><u>GS-US-626-6216 (STAR-121)</u></a>	<b>Temporarily Closed (Peoria, Bloomington, Galesburg, Ottawa, Pekin, Peru, Washington)</b> A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations
<a href="#"><u>MK 7684A-003</u></a>	<b>(Peoria only)</b> A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer

**METASTATIC - 2nd/3rd Line**

<a href="#"><u>EA5162</u></a>	Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients With Exon 20 Insertion Mutations in EGFR
<a href="#"><u>LUNGMAP</u></a>	<b>NEW Substudy!</b> A Master Protocol To Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated NSCLC. (SUB-STUDIES: <b>S1800D (CLOSED)</b> - A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy; <b>S1900E</b> - A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer ); <b>S1900F</b> - A Randomized Phase II Study of Carboplatin and Pemetrexed w/ or w/o Selpercatinib in Participants With Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy); <b>S1900G (NEW!)</b> - A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib With or Without Ramucirumab in Participants With EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer

<b><u>S2302 (Pragmatica)</u></b>	A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer ( <b>Pragmatica-Lung</b> )
<b>CANCER CONTROL (NSCLC Only)</b>	
<b><u>A211901</u></b>	<b><u>Not Actively Screening - Contact Navigator</u></b>   Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
<b><u>A212102</u></b>	<b>(Peoria, BLM, Canton, Gburg, Pekin, Peru, Ottawa, Wash)</b> Blinded Reference Set for Multicancer Early Detection Blood Tests ( <i>healthy cohort closed</i> )
<b><u>A222004</u></b>	<b><u>Not Actively Screening - Contact Navigator</u></b>   A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
<b><u>EAQ202</u></b>	Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials ( <i>breast, leukemia, lymphoma, and white non-hispanic cohorts closed to accrual</i> )
<b>JOVIALITY 23289</b>	<b>(Peoria only)</b> Safety and Acceptability: Virtual Reality for Psychotherapy Delivery in Lung Cancer Patients of Illinois CancerCare
<b><u>S2108CD</u></b>	<b>(Peoria, Bloomington, Galesburg, Canton, Ottawa, Pekin)</b> A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
<b><u>S1912CD</u></b>	<b><u>Not Actively Screening - Contact Navigator</u></b>   A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention ( <b>CREDIT</b> )
<b><u>S2013</u></b>	<b>(Peoria, Bloomington, Galesburg, Pekin, Washington)</b> Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study ( <b>I-CHECKIT</b> )
<b><u>URCC-18007</u></b>	Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue - <i>at least 2 months out from surgery/tx/radiation</i>
<b><u>URCC 19185</u></b>	<b>(Peoria Only)</b> Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)
<b><u>URCC 21038</u></b>	<b>(Peoria, Bloomington, Galesburg, Pekin, Washington)</b> Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
<b><u>WF-1901</u></b>	Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)

**PANCREATIC**

Navigator - Carrie x3621

<p><b><u>EA2186</u></b></p>	<p>A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients With Treatment Naïve Metastatic Pancreatic Cancer (GIANT)</p>
<p><b><u>EA2192</u></b></p>	<p>A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation (APOLLO)</p>
<p><b><u>S2001</u></b></p>	<p>Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations</p>
<p><b><u>S2104 - JIT Trial</u></b></p>	<p>Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors</p>



## PROSTATE

Navigator - Carrie x3621

### ADJUVANT

[GU008](#)

**(RT at Glen Oak, Carle)** Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE): *Intensifying Treatment for Node Positive Prostate Cancer by Varying the Hormonal Therapy*

[GU009](#)

**(RT at Glen Oak, Galesburg, Carle, Rt 91)** Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (**PREDICT-RT\***)

[GU010](#)

**(RT at Carle)** Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

### METASTATIC

[A032101](#)

A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): A-DREAM

[C2321001](#)

**(Peoria only)** A Phase I Dose Escalation and Expanded Cohort Study of PF-06821497 in the Treatment of Adult Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL)

[A031902 / CASPAR](#)

**Temporarily Suspended** | A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer

<b><u>GU011</u></b>	<b>(RT at Glen Oak and Carle)</b> A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadioTHErapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)
<b><u>S1802</u></b>	<b>(RT at Glen Oak, SJMC &amp; Carle)</b> Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

## RENAL CELL

Navigator - Carrie x3621

<a href="#"><u>A031704</u></a>	PD-Inhibitor (nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer (PDIGREE)
<a href="#"><u>MK 6482-011</u></a>	<b>(Peoria, Bloomington, Galesburg, Pekin)</b> An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy
<a href="#"><u>S2200</u></a>	A Phase II Randomized Trial of Cabozantinib (NSC #761968) With or Without Atezolizumab (NSC #783608) in Patients With Advanced Papillary Renal Cell Carcinoma (PAPMET2)

## RADIATION TRIALS

Navigator - Jessica x3615

CANCER CONTROL	
<a href="#"><u>WF-1801</u></a>	A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy
ANAL	
<a href="#"><u>EA2182</u></a>	<b>(Carle and Glen Oak)</b> A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
BLADDER	
<a href="#"><u>A032002</u></a>	<b>Temporarily Closed (RT at Glen Oak)</b> Phase II Randomized Trial of Atezolizumab Versus Atezolizumab and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (ART)
<a href="#"><u>EA8185</u></a>	<b>(RT pending at Glen Oak &amp; Rt-91)</b> Phase 2 Study of Bladder-Sparing Chemoradiation With MEDI4736 (Durvalumab) in Clinical Stage 3, Node Positive Bladder Cancer (INSPIRE)
<a href="#"><u>S1806</u></a>	<b>(Glen Oak, SJMC, Carle and Galesburg)</b> Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer
BRAIN	
<a href="#"><u>N0577</u></a>	<b>(Glen Oak, RT 91, and Carle)</b> Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
BRAIN METS	
<a href="#"><u>BN012</u></a>	<b>(RT at Carle)</b> A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases
<a href="#"><u>CCTG CE.7</u></a>	<b>(Glen Oak, Carle)</b> - A Phase III Trial of Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases
<a href="#"><u>WF-2201</u></a>	<b>(Glen Oak; Pending at Rt 91)</b> - Hypofractionated Radiotherapy vs Single Fraction Radiosurgery For Brain Metastasis Patients On Immunotherapy ( <b>HYPOGRYPHE</b> )

<b>BREAST</b>	
<b><u>BR007</u></b>	<b>(Galesburg, Glen Oak, Rt 91, Carle, SJMC)</b> Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
<b><u>MA.39</u></b>	<b>(Glen Oak)</b> Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
<b>HEAD &amp; NECK</b>	
<b><u>EA3161</u></b>	<b>(Glen Oak, Carle, Galeburg)</b> A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
<b><u>HN005</u></b>	<b>REOPENED!</b> <b>(Galesburg, Glen Oak)</b> A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
<b><u>HN009</u></b>	<b>(RT at Carle)</b> Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100 mg/m <sup>2</sup> ) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (40 mg/m <sup>2</sup> ) for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
<b>MERKEL CELL</b>	
<b><u>EA6174</u></b>	<b>Temporarily Closed</b> <b>(Glen Oak, Carle and Galesburg)</b> A Phase III Randomized Trial Comparing Adjuvant MK3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
<b>NSCLC</b>	
<b><u>EA5181</u></b>	<b>(Carle, Glen Oak, Rt-91, and Galesburg)</b> Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
<b><u>LU008</u></b>	<b>NEW!</b> <b>(RT credentialing pending)</b> Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer
<b><u>S1914</u></b>	<b>(Glen Oak, Carle, Galesburg, SJMC)</b> Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
<b>PROSTATE</b>	

<u><b>GU008</b></u>	<b>(RT at Glen Oak, Carle)</b> Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE): <i>Intensifying Treatment for Node Positive Prostate Cancer by Varying the Hormonal Therapy</i>
<u><b>GU009</b></u>	<b>(RT at Glen Oak, Galesburg, Carle, Rt 91)</b> Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation ( <b>PREDICT-RT*</b> )
<u><b>GU010</b></u>	<b>(RT at Carle)</b> Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
<u><b>GU011</b></u>	<b>(RT at Glen Oak &amp; Carle)</b> A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiothERapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)
<u><b>S1802</b></u>	<b>(Glen Oak, SJMC &amp; Carle)</b> Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
<u><b>WF-1802</b></u>	<b>(Glen Oak, Rt-91, Carle, Galesburg)</b> Influence of Primary Treatment for Prostate Cancer on Work Experience (PCW)
<b>SCLC</b>	
<u><b>NRG CC009</b></u>	<b>(Glen Oak, Carle)</b> - Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer
<u><b>S1827</b></u>	<b>(Glen Oak, Galesburg, SJMC, Carle)</b> A Randomized Phase III Trial of MRI Surveillance With or Without Prophylactic Cranial Irradiation (PCI) in Small-Cell Lung Cancer

## SMALL CELL LUNG CANCER

Navigator - Ashton x3611

<p><a href="#"><u>NRG CC009</u></a></p>	<p><b>(RT at Glen Oak, Carle)</b> - Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer</p>
<p><a href="#"><u>GO43104</u></a></p>	<p><b>(Peoria, Bloomington, Galesburg, Ottawa, Pekin, Peru, Washington)</b> A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin In Combination With Atezolizumab Compared With Atezolizumab As Maintenance Therapy In Participants With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Followiing First-Line Induction Therapy With Carboplatin, Etoposide and Atezolizumab</p>
<p><a href="#"><u>S1827</u></a></p>	<p><b>(RT at Glen Oak, Galesburg, SJMC, Carle)</b> A Randomized Phase III Trial of MRI Surveillance With or Without Prophylactic Cranial Irradiation (PCI) in Small-Cell Lung Cancer</p>
<p><a href="#"><u>TP-CA-003 (Sculptor)</u></a></p>	<p><b>(Peoria, Blm, Canton, Gburg, Ottawa, Pekin, Peru, Washington)</b> A Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients with Small Cell Lung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays (TEMPUS)</p>